Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. (Q50085065)
Jump to navigation
Jump to search
scientific article published on 28 October 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. |
scientific article published on 28 October 2017 |
Statements
1 reference
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. (English)
1 reference
Koutaro Yokote
Eiichi Araki
Hideki Suganami
Shizuya Yamashita
K-877 Study Group
28 October 2017
1 reference